# Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

> **NCT06092879** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 201 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **OTHER:** Asciminib

## Key facts

- **NCT ID:** NCT06092879
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2026-12-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06092879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06092879, "Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06092879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*